Does an integrated outreach intervention targeting multiple stages of early psychosis improve the identification of individuals at clinical high risk?

Sarah V. McIlwaine; Gerald Jordan; Marita Pruessner; Ashok Malla; Kia Faridi; Srividya N. Iyer; Ridha Joober; Jai L. Shah

doi:10.1111/eip.12750

Does an integrated outreach intervention targeting multiple stages of early psychosis improve the identification of individuals at clinical high risk?

Sarah V. McIlwaine, Gerald Jordan, Marita Pruessner, Ashok Malla, Kia Faridi, Srividya N. Iyer, Ridha Joober, Jai L. Shah^*

^*Corresponding author for this work

Psychology

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Aims: To explore the impact of a targeted case identification intervention, with training and education regarding first-episode psychosis and clinical high-risk syndromes, on the referral and identification of those at high risk. Methods: Using a historical control design, referral information from pre-intervention and post-intervention periods was collected via administrative data and clinician notes from a catchment-based early psychosis service. Results: A significant increase in the number of referrals sent to the service's clinical high-risk unit was observed following the intervention (P = 0.01). The proportion of referrals eligible was significantly higher post-intervention (P = 0.03), with the majority (26/44, 59.1%) referred via the first-episode psychosis service unit. Conclusions: An integrated outreach intervention for both first-episode psychosis and the clinical high-risk state was effective in increasing referrals of eligible cases to the service's at-risk unit. Rather than being stage-specific, targeted case identification strategies and service integration should span across the early stages of psychosis.

Original language	English
Pages (from-to)	989-992
Number of pages	4
Journal	Early Intervention in Psychiatry
Volume	13
Issue number	4
DOIs	https://doi.org/10.1111/eip.12750
Publication status	Published - Aug 2019

Bibliographical note

Funding Information:
S.V.M. has received funds to support her graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Québec-Santé; ACCESS Open Minds; and the Canadian Institutes of Health Research. G.J. has received funds to support his graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Québec-Santé, and the Canadian Insititutes of Health Research. M.P. was funded by the NARSAD Young Investigator Award and Support by the Golden Family Foundation. A.M. has received funds from the Fonds de recherche du Québec-Santé, The National Institutes of Health Research, Grand Challenges Canada, and the Canadian Institutes of Health Research. He was also funded through the Canadian Research Chair Program and received research funding unrelated to the present study from BMS, Pfizer, Otsuka, Lundbeck, and an honoraria related CME lectures and advisory board participation from BMS, Otsuka, Sunnovian, Lundbeck, and Pfizer. Finally, he received initial funding for the Clinical for the Assessment of Youth at-Risk by the EJLB and Zubhin foundations. K.F. has no interest to declare. S.N.I. was funded by the Fonds de recherche du Québec-Santé and the Canadian Institutes of Health Research. R.J. has received funds from the Fonds de recherche du Québec-Santé; and the Canadian Institutes of Health Research. He sits on the advisory boards and speakers' bureaus of Pfizer Canada and Janssen Ortho Canada; he has received grant funding from them and from AstraZeneca. He has received honoraria from Janssen Ortho Canada for CME presentations and royalties for Henry Stewart talks. J.L.S. has received funding from the Fonds de recherche du Québec-Santé.

Funding Information:
S.V.M. has received funds to support her graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Qu?bec-Sant?; ACCESS Open Minds; and the Canadian Institutes of Health Research. G.J. has received funds to support his graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Qu?bec-Sant?, and the Canadian Insititutes of Health Research. M.P. was funded by the NARSAD Young Investigator Award and Support by the Golden Family Foundation. A.M. has received funds from the Fonds de recherche du Qu?bec-Sant?, The National Institutes of Health Research, Grand Challenges Canada, and the Canadian Institutes of Health Research. He was also funded through the Canadian Research Chair Program and received research funding unrelated to the present study from BMS, Pfizer, Otsuka, Lundbeck, and an honoraria related CME lectures and advisory board participation from BMS, Otsuka, Sunnovian, Lundbeck, and Pfizer. Finally, he received initial funding for the Clinical for the Assessment of Youth at-Risk by the EJLB and Zubhin foundations. K.F. has no interest to declare. S.N.I. was funded by the Fonds de recherche du Qu?bec-Sant? and the Canadian Institutes of Health Research. R.J. has received funds from the Fonds de recherche du Qu?bec-Sant?; and the Canadian Institutes of Health Research. He sits on the advisory boards and speakers' bureaus of Pfizer Canada and Janssen Ortho Canada; he has received grant funding from them and from AstraZeneca. He has received honoraria from Janssen Ortho Canada for CME presentations and royalties for Henry Stewart talks. J.L.S. has received funding from the Fonds de recherche du Qu?bec-Sant?.

Publisher Copyright:
© 2018 John Wiley & Sons Australia, Ltd

Keywords

clinical high risk for psychosis
early case identification
first-episode psychosis
specialized early intervention services
targeted case identification

ASJC Scopus subject areas

Phychiatric Mental Health
Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/eip.12750

Cite this

@article{6d1b801fcfa14fd3bbc18a435b96067e,

title = "Does an integrated outreach intervention targeting multiple stages of early psychosis improve the identification of individuals at clinical high risk?",

abstract = "Aims: To explore the impact of a targeted case identification intervention, with training and education regarding first-episode psychosis and clinical high-risk syndromes, on the referral and identification of those at high risk. Methods: Using a historical control design, referral information from pre-intervention and post-intervention periods was collected via administrative data and clinician notes from a catchment-based early psychosis service. Results: A significant increase in the number of referrals sent to the service's clinical high-risk unit was observed following the intervention (P = 0.01). The proportion of referrals eligible was significantly higher post-intervention (P = 0.03), with the majority (26/44, 59.1%) referred via the first-episode psychosis service unit. Conclusions: An integrated outreach intervention for both first-episode psychosis and the clinical high-risk state was effective in increasing referrals of eligible cases to the service's at-risk unit. Rather than being stage-specific, targeted case identification strategies and service integration should span across the early stages of psychosis.",

keywords = "clinical high risk for psychosis, early case identification, first-episode psychosis, specialized early intervention services, targeted case identification",

author = "McIlwaine, {Sarah V.} and Gerald Jordan and Marita Pruessner and Ashok Malla and Kia Faridi and Iyer, {Srividya N.} and Ridha Joober and Shah, {Jai L.}",

note = "Funding Information: S.V.M. has received funds to support her graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Qu{\'e}bec-Sant{\'e}; ACCESS Open Minds; and the Canadian Institutes of Health Research. G.J. has received funds to support his graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Qu{\'e}bec-Sant{\'e}, and the Canadian Insititutes of Health Research. M.P. was funded by the NARSAD Young Investigator Award and Support by the Golden Family Foundation. A.M. has received funds from the Fonds de recherche du Qu{\'e}bec-Sant{\'e}, The National Institutes of Health Research, Grand Challenges Canada, and the Canadian Institutes of Health Research. He was also funded through the Canadian Research Chair Program and received research funding unrelated to the present study from BMS, Pfizer, Otsuka, Lundbeck, and an honoraria related CME lectures and advisory board participation from BMS, Otsuka, Sunnovian, Lundbeck, and Pfizer. Finally, he received initial funding for the Clinical for the Assessment of Youth at-Risk by the EJLB and Zubhin foundations. K.F. has no interest to declare. S.N.I. was funded by the Fonds de recherche du Qu{\'e}bec-Sant{\'e} and the Canadian Institutes of Health Research. R.J. has received funds from the Fonds de recherche du Qu{\'e}bec-Sant{\'e}; and the Canadian Institutes of Health Research. He sits on the advisory boards and speakers' bureaus of Pfizer Canada and Janssen Ortho Canada; he has received grant funding from them and from AstraZeneca. He has received honoraria from Janssen Ortho Canada for CME presentations and royalties for Henry Stewart talks. J.L.S. has received funding from the Fonds de recherche du Qu{\'e}bec-Sant{\'e}. Funding Information: S.V.M. has received funds to support her graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Qu?bec-Sant?; ACCESS Open Minds; and the Canadian Institutes of Health Research. G.J. has received funds to support his graduate studies from the Department of Psychiatry at McGill University; Fonds de recherche du Qu?bec-Sant?, and the Canadian Insititutes of Health Research. M.P. was funded by the NARSAD Young Investigator Award and Support by the Golden Family Foundation. A.M. has received funds from the Fonds de recherche du Qu?bec-Sant?, The National Institutes of Health Research, Grand Challenges Canada, and the Canadian Institutes of Health Research. He was also funded through the Canadian Research Chair Program and received research funding unrelated to the present study from BMS, Pfizer, Otsuka, Lundbeck, and an honoraria related CME lectures and advisory board participation from BMS, Otsuka, Sunnovian, Lundbeck, and Pfizer. Finally, he received initial funding for the Clinical for the Assessment of Youth at-Risk by the EJLB and Zubhin foundations. K.F. has no interest to declare. S.N.I. was funded by the Fonds de recherche du Qu?bec-Sant? and the Canadian Institutes of Health Research. R.J. has received funds from the Fonds de recherche du Qu?bec-Sant?; and the Canadian Institutes of Health Research. He sits on the advisory boards and speakers' bureaus of Pfizer Canada and Janssen Ortho Canada; he has received grant funding from them and from AstraZeneca. He has received honoraria from Janssen Ortho Canada for CME presentations and royalties for Henry Stewart talks. J.L.S. has received funding from the Fonds de recherche du Qu?bec-Sant?. Publisher Copyright: {\textcopyright} 2018 John Wiley & Sons Australia, Ltd",

year = "2019",

month = aug,

doi = "10.1111/eip.12750",

language = "English",

volume = "13",

pages = "989--992",

journal = "Early Intervention in Psychiatry",

issn = "1751-7885",